␤-Spectrin is an erythrocyte membrane protein that is defective in many patients with abnormalities of red blood cell shape including hereditary spherocytosis and elliptocytosis. It is expressed not only in erythroid tissues but also in muscle and brain. We wished to determine the regulatory elements that determine the tissuespecific expression of the ␤-spectrin gene. We mapped the 5-end of the ␤-spectrin erythroid cDNA and cloned the 5-flanking genomic DNA containing the putative ␤-spectrin gene promoter. Using transfection of promoter/reporter plasmids in human tissue culture cell lines, in vitro DNase I footprinting analyses, and gel mobility shift assays, a ␤-spectrin gene erythroid promoter with two binding sites for GATA-1 and one site for CACCCrelated proteins was identified. All three binding sites were required for full promoter activity; one of the GATA-1 motifs and the CACCC-binding motif were essential for activity. The ␤-spectrin gene promoter was able to be transactivated in heterologous cells by forced expression of GATA-1. In transgenic mice, a reporter gene directed by the ␤-spectrin promoter was expressed in erythroid tissues at all stages of development. Only weak expression of the reporter gene was detected in muscle and brain tissue, suggesting that additional regulatory elements are required for high level expression of the ␤-spectrin gene in these tissues.
Spectrin, the most abundant protein of the erythrocyte membrane skeleton, is composed of two structurally similar but nonidentical proteins, ␣-and ␤-spectrin, encoded by separate genes. ␣-and ␤-spectrin are composed primarily of homologous 106-amino acid repeats that fold into three antiparallel ␣-helices connected by short nonhelical segments (1, 2) . ␣-and ␤-spectrin combine to form heterodimers, which in turn selfassociate to form tetramers and higher order oligomers to form a lattice-like structure that is critical for erythrocyte membrane stability as well as erythrocyte shape and deformability. In the red cell, spectrin maintains cellular shape, regulates the lateral mobility of integral membrane proteins, and provides structural support for the lipid bilayer (3, 4) . Quantitative and qualitative disorders of both ␣-and ␤-spectrin have been associated with abnormalities of erythrocyte shape including hereditary spherocytosis and hereditary elliptocytosis (5, 6) .
Erythrocyte ␤-spectrin contains binding sites for actin, protein 4.1, and ankyrin, as well as the ␣␤-spectrin self-association site (3) . The human ␤-spectrin erythroid cDNA transcript contains an open reading frame of 6411 bp 1 (7) . The deduced amino acid sequence predicts a peptide of 2137 amino acids with a predicted molecular mass of 246 kDa. The ␤-spectrin erythroid cDNA transcript is encoded by 32 exons (8) . The chromosomal gene, localized to 14q23-q24.2 (9) , spans over Ͼ100 kilobase pairs of genomic DNA.
␤-Spectrin transcripts have also been identified in nonerythroid tissues including heart, skeletal muscle, brain, platelets, trachea, and lens (10 -22) . In the nervous system tissue, ␤-spectrin is expressed in the granular cells of the cerebellum and in regions of the neocortex (15) . In muscle, there are several populations of ␤-spectrin, including an immunoreactive isoform clustered with the acetylcholine receptor (10, 17, 18, (23) (24) (25) (26) . In some nonerythroid tissues, ␤-spectrin may exist as homodimers or homotetramers, without an ␣-spectrin partner (15, 17, 18, 25) . In nonerythroid tissues, spectrin may establish or maintain local concentrations of proteins of the plasma membrane, participate in the early stages of cell junction formation, and regulate access of secretory vesicles to the plasma membrane as well as play a role in maintaining the structural integrity of cellular membranes (3, 27, 28) .
The mechanisms by which ␤-spectrin has acquired distinct isoforms with specialized functions are beginning to be revealed. The isoform diversity of ␤-spectrin arises from both different gene products and from differential, alternative splicing of the same gene product. In humans, the cDNAs for two ␤-spectrin proteins have been cloned, and their gene products have been studied (4, 7, 21, 29 -32) . These spectrins share similar antigenic sites and domain structures, differing in a number of ways such as their cellular patterns of expression and their relative affinities of binding to ankyrin and band 3. In brain and muscle, an alternatively spliced mRNA isoform of the ␤-spectrin gene has been identified. This tissue-specific, differential processing occurs at the 3Ј-end of the ␤-spectrin pre-mRNA, generating a ␤-spectrin cDNA isoform in brain and muscle encoded by 36 exons (cf. 32 in erythroid) (7, 8, 11, 21) . The predicted isoform contains an COOH terminus different from that in erythrocyte, with the last 22 amino acids of erythrocyte ␤-spectrin replaced by a new sequence of 213 amino acids.
There are no data regarding the molecular mechanisms that regulate the tissue-specific or developmental stage-specific expression of ␤-spectrin isoforms. For example, it is unknown whether or not isoforms of ␤-spectrin are transcribed from the same gene by tissue-specific utilization of alternate promoters. This report describes the identification and characterization of a promoter of the human ␤-spectrin gene that directs high level expression in erythroid cells at all stages of development. This expression of the human ␤-spectrin gene is mediated by a compact promoter that requires GATA-1 and CACCC-binding proteins for its activity. This promoter does not direct high level activity in nonerythroid tissues, including brain and muscle, suggesting that additional regulatory elements are required for expression of the ␤-spectrin gene in these tissues.
MATERIALS AND METHODS
RNA Preparation-Total RNA was prepared from human fetal liver tissue; human bone marrow; or the human tissue culture cell line K562 (chronic myelogenous leukemia in blast crisis with erythroid characteristics, ATCC, CCL 243), HEL (erythroleukemia, ATCC, TIB 180), or HeLa (epithelial-like carcinoma, cervix, CCL 2) using the guanidinium thiocynate-chloroform method as described (33) .
5Ј-Rapid Amplification of cDNA Ends (RACE)-1 g of total human fetal liver RNA was reverse transcribed using primer A (Table I ) and avian myeloblastosis virus reverse transcriptase (Promega, Madison, WI). Single-stranded oligonucleotide ligation and PCR amplification were carried out as described using primers B ϩ D and C ϩ D (34, 35) . Amplification products were subcloned and sequenced.
Genomic Cloning-A human ␤-spectrin cDNA fragment corresponding to the 5Ј-end of the coding region, V252 (7), was used as hybridization probe to screen a human genomic DNA library. The library is a Charon 4A bacteriophage library containing fragments of genomic DNA partially digested with AluI and HaeIII with EcoRI linkers added. Selected recombinants that hybridized to the screening probe were purified and subcloned into pGEM-7Z plasmid vectors (Promega). Subcloned fragments were analyzed by restriction endonuclease digestion, Southern blotting, and nucleotide sequencing.
Mapping the Transcription Initiation Site-The transcription initiation site of the erythroid ␤-spectrin cDNA was determined using an RNase protection assay. A 32 P-labeled antisense RNA probe was synthesized by transcription with T7 polymerase of a 180-bp DdeI-ApaI fragment corresponding to the first exon and 5Ј-flanking sequences of FIG. 1. The 5-end of the human ␤-spectrin gene. A, structure of the 5Ј-end of the human ␤-spectrin-1 erythroid cDNA. A diagram of the 5Ј-end of the human ␤-spectrin cDNA is shown. The location of the initiation codon is shown, as is the location of intron/exon boundaries. Sequence obtained by 5Ј-RACE is denoted by a hatched box. Oligonucleotide primers used in 5Ј-RACE are denoted by the arrows. The location of the probe used in genomic library screening, V252, and the end of the 5Ј-most ␤-spectrin cDNA clone (7) are shown. B, genomic organization of the 5Ј-end of the human ␤-spectrin gene. Five overlapping clones containing the ␤-spectrin gene were isolated from a human genomic DNA library. These clones spanned a distance of over 40 kilobase pairs. Clone 27 contained exon 1 of the ␤-spectrin erythroid cDNA in a 2.0-kilobase pair EcoRI fragment. A restriction map of clone 27 with EcoRI (E) and BamHI (B) is shown.
the human ␤-spectrin gene. The probe (1 ϫ 10 5 cpm/assay) was hybridized to template RNA at 42°C for 16 h. Templates in these reactions were 20 g of total human fetal liver RNA, 20 g of total RNA from the human cell lines K562 and HEL, or 20 g of tRNA. Hybrids were digested with a mixture of the nucleases RNase A and RNase T1 (0.125 units and 5 units, respectively, per assay) at 37°C for 30 min. After digestion, protected fragments were detected by autoradiography after electrophoresis in 6% polyacrylamide, 7 M urea gels. Further increases in nuclease concentration or length of incubation did not alter the pattern of the protected fragment (not shown).
Nucleotide Sequencing-Nucleotide sequencing was performed using the dideoxy chain termination method of Sanger et al. (36) with T7 DNA polymerase (Sequenase; U.S. Biochemical Corp.). The sequencing primers were the Sp6 or T7 vectors of the pGEM-7Z plasmid vector or, for some reactions, synthetic oligonucleotides corresponding to known cDNA sequences (Table I) . Deoxyinosine trisphosphate was substituted for deoxyguanosine trisphosphate to resolve band compressions and ambiguities.
Preparation of Nuclear Extracts-Nuclear extracts were prepared from K562, HEL, MEL (murine erythroleukemia, NIGMS GM00086E), and HeLa cells by hypotonic lysis followed by high salt extraction of nuclei as described by Andrews and Faller (37) .
DNase I Footprinting in Vitro-Probes for DNase I footprinting were by produced by PCR amplification of plasmid p173 (see below) as FIG. 2. Mapping the 5-end of the human ␤-spectrin cDNA. RNase mapping was carried out using a riboprobe (left) and 10 g of K562, HEL, HL60 total RNA, or tRNA as template. The size of the extension products, 113 nucleotides (right), indicates that the 5Ј-end of the mRNA is located at position Ϫ162 relative to the adenosine of the initiator methionine codon. The cDNA sequence of this additional 5Ј-untranslated cDNA was determined by 5Ј-RACE and is shown in Fig. 4 . template and a pair of oligonucleotide primers that flank the plasmid polylinker. One oligonucleotide was 5Ј-end-labeled with [ 32 P]ATP using polynucleotide kinase prior to use in PCR. Reaction mixes contained 1-20 g of MEL cell nuclear extracts, 20,000 cpm of labeled probe, and 1 g of poly(dI-dC) (38) . After digestion with DNase I, samples were electrophoresed in 6% polyacrylamide gels, and the gels were dried and subjected to autoradiography.
Cell Culture-The tissue culture cell lines K562 and HEL (erythroid), SH-SY5Y (neural), and HeLa (nonerythroid) were used to study expression of the putative promoter of the gene. K562, MEL, and SH-Sy5Y cells were maintained in RPMI 1640 medium containing 10% fetal calf serum. HeLa cells were maintained in Eagle's minimal essential media supplemented with 10% fetal calf serum.
Preparation of Promoter-Reporter Plasmids for Transfection Assays-Test plasmids were prepared by inserting a 700-bp fragment of the 5Ј-flanking ␤-spectrin genomic DNA upstream of the firefly luciferase reporter gene in the plasmid pGL2B (Promega) in both orientations. These plasmids were designated p700-forward and p700-reverse, respectively. Serial truncations of this 700-bp fragment in the pGL2B plasmid were constructed using convenient restriction enzyme sites or PCR amplification. Test plasmids were sequenced to exclude cloning or PCR-generated artifacts.
Transient Transfection Analyses-All plasmids tested were purified using Qiagen columns (Qiagen, Inc., Chatsworth, CA) or cesium chloride plasmid purification, and at least two preparations of each plasmid were tested in triplicate. 10 7 K562, MEL, and SH-SY5Y cells were transfected by electroporation with a single pulse of 300 V at 960 microfarads with 20 g of test plasmid and 0.5 g of pCMV␤, a mammalian reporter plasmid expressing ␤-galactosidase driven by the human cytomegalovirus immediate early gene promoter (CLONTECH, Palo Alto, CA). 10 5 HeLa cells were transfected with 2.0 g of test plasmid and 0.25 g of the pCMV␤ plasmid by lipofection using 4 l of Lipofectamine (Life Technologies, Inc.). Twenty-four hours after transfection, cells were harvested and lysed, and the levels of both luciferase and ␤-galactosidase activity were determined in cell extracts. All assays were performed in triplicate. Differences in transfection efficiency were determined by co-transfection with the pCMV␤ plasmid.
COS cells ( 10 7 ) were transfected with 20 g of the expression plasmids pMT/BKLF (39) (a kind gift of Drs. M. Crossley and S. Orkin) or pSG5/erythroid Kruppel-like factor (EKLF) (40) (a kind gift of Dr. J. Bieker) as described above. Forty-eight hours after transfection, nuclear extracts were prepared for use in gel shift analyses. Antibodies to GATA-1 and Sp1 were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibodies to BKLF and EKLF were a kind gift of Drs. M. Crossley and S. Orkin.
Gel Mobility Shift Analyses-Binding reactions were carried out as described (41) . Competitor oligonucleotides were added at molar excesses of 10-or 100-fold. Resulting complexes were separated by electrophoresis through 6% polyacrylamide gels in 0.5ϫ Tris-borate-EDTA at 21°C at 200 watts for 2 h. Gels were dried and subjected to autoradiography. Generation of Transgenic Mice-Transgenic mice were generated as described in Hogan et al. (42) and Sabatino et al. (43) . Fertilized eggs were collected from superovulated FVB/N female mice approximately 9 h after mating to CB6F1 male mice. After purification, ␤-spectrin promoter/ A ␥-globin DNA fragments were microinjected into the male pronucleus of fertilized eggs. The injected eggs were transferred into pseudopregnant CB6F1 foster mothers. Founders were identified by Southern blotting of genomic DNA obtained from tail biopsies. Copy number was determined by comparing transgenic mouse DNA to K562 DNA. Founder animals were crossed to FVB/N mice for propagation.
Preparation of Promoter-Reporter Plasmids for Transgenic
Analysis of Transgene Expression-Total cellular RNA was extracted from mouse tissues, including 10.5-day embryo blood cells, 13.5-day fetal livers, and adult reticulocytes using TRIZOL reagent (Life Technologies). The tissue-specific pattern of expression of the erythroid ␤-spectrin promoter/ A ␥-globin reporter transgene was analyzed using an RNase protection assay. Linear DNA templates for the RNase protection assay were prepared by EcoRI digestion of a human ␤-spectrin/ A ␥-globin plasmid or by HindIII digestion of a murine ␣-globin plasmid. Templates were purified by agarose gel electrophoresis. The 32 P-labeled antisense RNA probe was synthesized by transcription with T7 polymerase (MAXIscript In Vitro Transcription Kit; Ambion, Inc., Austin, TX). The probe (1 ϫ 10 5 cpm/assay) was hybridized to template RNA at 42°C overnight. Templates in these reactions were 1 g of total murine spleen or bone marrow RNA; 10 g of total RNA from muscle, brain, heart, liver, kidney, lung, or testis; or 10 g of tRNA. Hybrids were digested with a mixture of the nucleases RNase A and RNase T1. After digestion, protected fragments were detected by autoradiography after electrophoresis in 8% nondenaturing polyacrylamide gels.
Computer Analyses-Computer-assisted analyses of derived nucleotide sequences were performed utilizing the sequence analysis software package of the University of Wisconsin Genetics Computer Group (44) and the BLAST algorithm, National Center for Biotechnology Information (Bethesda, MD) (45) .
RESULTS

Cloning of Chromosomal Gene: Isolation and Analysis of
Recombinant Clones-Primary screening of a human genomic DNA library with the ␤-spectrin cDNA probe V252 (Fig. 1A) yielded six hybridization-positive plaques. Selected recombinants were analyzed, and one clone was identified, 27, that spanned ϳ21 kilobase pairs of DNA containing the ␤-spectrin gene. A limited restriction map of this region is shown in Fig.  1B .
Mapping the Human ␤-Spectrin Erythroid mRNA Transcription Initiation Site and Identification of 5Ј cDNA Sequences-To identify the 5Ј-end of the human ␤-spectrin cDNA, RNase mapping with RNase A and RNase T1 nucleases was performed. These experiments identified a single transcription initiation site (Fig. 2 ) and predicted the presence of an additional 64 bp in the mRNA upstream of the 5Ј-end of the sequence obtained from cDNA cloning. These additional 64 bp of upstream 5Ј-untranslated sequence were obtained by 5Ј-RACE. Sequences obtained by RACE were verified by comparison with corresponding genomic DNA sequences (Fig. 3) . The sequences around the transcription start site, GCA ϩ1 CCAG, closely match transcription initiation recognition sequences, YYA ϩ1 NWYY (46) . No additional ATGs were present in the 5Ј-untranslated sequences. Taken together, these data suggest that this sequence is at or very near the 5Ј-end of the human ␤-spectrin erythroid cDNA.
The 5Ј-Flanking Genomic DNA Sequence of the Human ␤-Spectrin-1 Gene Exhibits Features of an Erythroid Gene Promoter-The nucleotide sequence of the 5Ј-flanking genomic DNA upstream of the human ␤-spectrin cDNA transcription start site is shown in Fig. 3 . Inspection of the sequence reveals a lack of consensus TATA or CCAAT sequences. Consensus sequences for a number of potential DNA-binding proteins, including GATA-1 (two sites) and Sp1/CACCC-related proteins, characteristics of an erythroid gene promoter, are present in the 5Ј-flanking sequences. GATA motifs bind GATA-1, a zinc finger transcription factor essential for erythroid development. GC or G(T/C)ACC motifs are the binding sites for a number of transcription factor proteins, including ubiquitous Sp1 and Sp1-like proteins, and cell-restricted proteins such as EKLF.
A ␤-Spectrin-1 Gene Promoter Fragment Is Active in Erythroid Cells-To investigate if the region from Ϫ623 to ϩ77 was capable of directing expression of a reporter gene in cultured mammalian cells, test plasmids p700-forward and p700-reverse were transiently transfected into erythroid (K562 and MEL), neural (SY5Y), or nonerythroid (NIH3T3) cells. The relative luciferase activity was determined 48 h after transfection and compared with the activity obtained with pGL2B, a negative control, the promoterless plasmid, and pGL2P, a positive control, the luciferase reporter gene under control of the SV40 early promoter. As shown in Fig. 4 , the putative ␤-spectrin gene erythroid promoter plasmid, p700-forward, directed high level expression of the luciferase reporter gene only in erythroid cells. The plasmid with the promoter in reverse orientation, p700-reverse, did not direct expression of the reporter gene in any of the cell lines.
Transient transfection analysis of deletions of this ␤-spectrin gene erythroid promoter fragment identified a 250-bp minimal promoter fragment, p173, that directed erythroid-specific expression of the reporter gene (Fig. 4) . The 250-bp minimal promoter fragment contains potential binding sites for GATA-1, as well as Sp1-and CACCC-related proteins, a combination shown to be adequate for expression of a minimal promoter in other erythroid-specific genes. There was minimal FIG. 5 . In vitro DNase I footprinting of the human ␤-spectrin promoter. In vitro DNase I footprinting of the human ␤-spectrin gene promoter was performed using erythroid (MEL) extracts as described under "Materials and Methods." Three protected sites were identified, two corresponding to GATA-1 consensus binding sites and the third to a long GC-rich region of sequences that are recognized by members of the Kruppel family of transcription factors as well as CACCC-related proteins.
TABLE I Oligonucleotide primers
Primer Sequence
The Human ␤-Spectrin Gene Erythroid Promoterto no reporter gene activity in transfected HeLa or SY5Y cells.
The ␤-Spectrin Erythroid Promoter Contains Binding Sites for GATA-1 and CGCC-and CACCC-related Binding Proteins-Consensus
sequences for a number of potential DNAbinding proteins, including GATA-1 and CACCC-related proteins, were present in the ␤-spectrin gene promoter. To identify binding sites for transcription factors within the ␤-spectrin promoter, DNase I footprinting analysis with nuclear extracts from MEL cells was performed (Fig. 5) . Footprints at three protected sites were observed. Two sites, sites 1 and 2, contain consensus binding sequences for GATA-1. The third site, site 3, consists of a long GC-rich region of sequences that are recognized by members of the Kruppel-like family of transcription factors as well as CACCC-related proteins.
GATA-1 Binds Both ␤-Spectrin Gene Promoter Sites in Vitro-
To determine if nuclear proteins could bind these GATA-1 sites in vitro, double-stranded oligonucleotides containing the corresponding ␤-spectrin promoter GATA-1 se- FIG. 6 . Gel mobility shift assays of footprinted sites 1 and 2 of the human ␤-spectrin gene promoter. Gel mobility shift assays using ␤-spectrin promoter oligonucleotides corresponding to footprinted sites 1 or 2, both of which contain GATA-1 consensus binding sequences, were performed using erythroid (MEL) nuclear extracts. A, the radiolabeled, double-stranded oligonucleotide used in lanes 1-6 corresponds to site 1; the radiolabeled, double-stranded oligonucleotide used in lanes 7-12 corresponds to site 2; and the radiolabeled, doublestranded oligonucleotide used in lanes 13 and 14 is a GATA-1 control. Increasing amounts of unlabeled, double-stranded oligonucleotide, self (lanes 3 and 4 and lanes 9 and 10) or control (lanes 5 and 6 and lanes 9 and 10), were added to the reactions as competitor. No complexes were obtained using HeLa extracts (not shown). B, gel mobility shift assays using ␤-spectrin promoter oligonucleotides corresponding to footprinted site 1 or 2, both of which contain GATA-1 consensus binding sequences, and a control GATA-1 oligonucleotide, were performed using erythroid (MEL) extracts. A GATA-1 antibody was added to the reaction mixtures where indicated.
quences (site 1, E ϩ F; site 2, G ϩ H; Table I ) or control sequences (I ϩ J; Table I ) (47) were prepared and used in gel shift analyses. When oligonucleotides containing either of the FIG. 7 . Gel mobility shift assays of footprinted site 3 of the human ␤-spectrin gene promoter. A, gel mobility shift assays using ␤-spectrin promoter oligonucleotides corresponding to footprinted site 3, which contains Sp1/CACCC consensus binding sequences, and MEL (erythroid) nuclear extracts. The radiolabeled, double-stranded oligonucleotide used in lanes 1-6 corresponds to site 3, and the radiolabeled, double-stranded oligonucleotide used in lanes 7-12 is a CACCC control. Increasing amounts of unlabeled, double-stranded oligonucleotide, site 3 ( lanes 3 and 4 and lanes 11 and 12), CACCC control (lanes 5 and 9) , or Sp1 control (lanes 6 and 10) were added to the reactions as compet-FIG. 8. Gel mobility shift assays of footprinted site 3 of the human ␤-spectrin gene promoter and antibodies to BKLF and EKLF. A, gel mobility shift assays using a ␤-spectrin promoter oligonucleotide corresponding to footprinted site 3, which contains Sp1/ CACCC consensus binding sequences and nuclear extracts from BKLFtransfected COS cells. A BKLF antibody was added to the reaction mixtures where indicated. B, gel mobility shift assays using ␤-spectrin promoter oligonucleotides corresponding to footprinted site 3 and nuclear extracts from EKLF-transfected COS cells. An EKLF antibody was added to the reaction mixtures where indicated. When nuclear extracts from untransfected COS cells were used in gel shift analyses, complexes migrating at the same location as those obtained using the ␤-globin CACCC control oligonucleotide were not seen (not shown).
itor. B, gel mobility shift assays using a ␤-spectrin promoter oligonucleotide corresponding to footprinted site 3 and a control Sp1 oligonucleotide, were performed using erythroid (MEL) extracts. An Sp1 antibody was added to the reaction mixtures where indicated.
footprinted GATA-1 sequences were used in gel shift analyses, a single retarded species was observed in MEL (erythroid) extracts (Fig. 6A ), but not in HeLa extracts (not shown). These species migrated at the same location as a control oligonucleotide containing a GATA-1 consensus sequence. This species was effectively competed both by an excess of unlabeled homologous oligonucleotide and by an excess of unlabeled control GATA-1 oligonucleotide. The inclusion of GATA-1 antisera abolished most or all of the DNA binding (Fig. 6B) . These data indicate that GATA-1 binds in vitro to sites 1 and 2 of the ␤-spectrin gene promoter.
CACCC-box Binding Proteins Bind to the ␤-Spectrin Gene Promoter GC-rich Site in Vitro-Site 3 identified by DNase I footprinting contains an extended GC-rich sequence, 5Ј-CCGC-CTCCCCGCCCCCGCCG-3Ј, a consensus binding site for CACCC-box-binding proteins. Although CACCC-box-binding proteins bind both CACCC and CGCCC sequences, they show distinct binding preferences (39, 48 -50) . To determine if the nuclear protein Sp1, BKLF, or EKLF binds this extended GCrich sequence in vitro, double-stranded oligonucleotides containing the corresponding ␤-spectrin promoter site 3 sequences (I ϩ J; Table I ) or control sequences (Sp1 M ϩ N (48, 51); CACCC O ϩ P (40); Table I ) were prepared and used in gel shift analyses. When double-stranded oligonucleotides containing the site 3 sequences were used in gel shift analyses with MEL extracts, one larger, slower migrating species and two smaller, faster migrating species were detected. These species migrated at the same location as those obtained using control oligonucleotides containing either CACCC (Fig. 7A) or Sp1 (not shown) consensus sequences. All three species were effectively competed by an excess of unlabeled homologous oligonucleotide and an excess of unlabeled CACCC or Sp1 control oligonucleotides. The inclusion of Sp1 antisera supershifted the larger, slower migrating species in the gel (Fig. 7B) .
To determine if the CACCC-box-binding transcription factors BKLF or EKLF could bind the ␤-spectrin gene promoter GC-rich site in vitro, gel shifts using nuclear extracts prepared from COS cells transfected with expression plasmids containing either BKLF or EKLF cDNAs and either the ␤-spectrin gene promoter site 3 oligonucleotide or a control ␤-globin CACCC oligonucleotide (Q ϩ R) (52) were performed. A major complex was identified in BKLF-transfected cells (Fig. 8A) . This complex migrated at the same location as the control ␤-globin CACCC control oligonucleotide. The complexes obtained with both the ␤-spectrin and ␤-globin oligonucleotides were supershifted with an anti-BKLF antibody. When extracts from EKLF-transfected cells were used in similar experiments, a major complex was identified using the ␤-globin CACCC consensus sequence oligonucleotide, and a very minor complex was identified using the ␤-spectrin site 3 oligonucleotide (Fig.  8B) . Both the ␤-globin and ␤-spectrin complexes migrated at the same location. Although the complexes were not completely competed away, the complexes obtained with both the ␤-spectrin and ␤-globin oligonucleotides were supershifted with an anti-EKLF antibody. Together, these data indicate that various CACCC-box-binding proteins bind to the ␤-spectrin gene promoter in vitro.
GATA-1 and CACCC-related Proteins Are Both Major Activators of the Human Erythroid ␤-Spectrin
Gene Promoter-To assess the relative importance of these transcription factor binding sites in promoter function, mutations were introduced into each of the three sites protected in DNase I footprinting experiments. Mutation of the site 1 GATA-1 consensus sequence (GATA to GTTA) reduced promoter activity by half (Fig.  4) . Mutating the site 2 GATA-1 consensus sequence in a similar manner (GATA to GTTA) reduced promoter activity to very low levels, indicating that this site is of major importance in the ␤-spectrin gene promoter. Mutation of the site 3 CACCC-binding consensus sequence (CCCGCCTCCCCGCCCCCGCC to AAAGGAAAGGAAAGGAAAAG) reduced promoter activity nearly to background, indicating that this site is of major importance in the ␤-spectrin gene promoter (Fig. 4) .
GATA-1, but Not BKLF or EKLF, Transactivates the ␤-Spectrin Gene Erythroid Promoter in Heterologous
Cells-None of the ␤-spectrin promoter fragments directed expression of a reporter gene in HeLa cells, but the addition of GATA-1 by co-transfection conferred promoter activity to a ␤-spectrin promoter fragment. Co-transfection of 1 g of a ␤-spectrin erythroid promoter fragment, p504, and increasing amounts of a GATA-1 cDNA expression plasmid resulted in increasing pro- moter activity with increasing amounts of GATA-1 plasmid (Fig. 9) . The ability of GATA-1 to transcriptionally activate the ␤-spectrin erythroid promoter in these cells, which do not contain this erythroid-specific factor, correlates with the inability of the ␤-spectrin erythroid promoter to function in these cells.
Co-transfection of 1 g of a ␤-spectrin erythroid promoter fragment, p504, and increasing amounts of a BKLF cDNA expression plasmid did not result in any change in promoter activity (Fig. 9) . Co-transfection of 1 g of the ␤-spectrin erythroid promoter fragment, p504, and increasing amounts of an EKLF cDNA expression plasmid resulted in essentially no change in promoter activity with increasing amounts of EKLF plasmid (Fig. 9) .
Transgenic Mice Express the ␤-Spectrin/ A ␥-Globin Transgene in Erythroid Cells at All Stages of Development-The role of the ␤-spectrin promoter fragment, p504, in directing expression of a reporter gene in vivo was examined. Three transgenic lines and two day 13.5 fetal livers containing the ␤-spectrin/ A ␥-globin transgene were analyzed (Fig. 10A) . RNase protection demonstrated that two of three ␤-spectrin/ A ␥-globin transgenic lines and one of two fetal livers expressed the ␤-spectrin/ A ␥-globin transgene in erythroid cells (Table II) . No ␤-spectrin/ A ␥-globin RNA was detected in erythroid cells of the third transgenic line or the other fetal liver. The number of transgenes in each line was estimated by Southern blot analyses to be between three and six copies per expressing animal.
After correction for copy number, the level of ␤-spectrin/ A ␥-globin mRNA was compared with the mRNA of the four murine ␣-globin genes. In all transgenic lines expressing the ␤-spectrin/ A ␥-globin transgene, the A ␥-globin reporter gene was expressed in day 10.5 yolk sac-derived peripheral blood cells, in day 13.5 fetal liver, and in adult reticulocytes, i.e. at all stages of erythroid development, at levels ranging from 12 to 37% of the levels of murine ␣-globin expression in the same cells. Cellulose acetate electrophoresis was performed to confirm the presence of ␥-globin chains in day 13.5 fetal liver and adult circulating erythrocytes. The fetal and adult erythrocytes of mice expressing the ␤-spectrin/ A ␥-globin transgene contained endogenous mouse hemoglobins as well as an additional hemoglobin band composed of two mouse ␣-globin chains and two human ␥-globin chains (43) . These results were confirmed by acid/urea gel electrophoresis and high pressure liquid chromatography analysis (not shown).
The ␤-spectrin/ A ␥-Globin Transgene Directs Lower Levels of Expression in Nonerythroid Tissues-In the two transgenic lines expressing the ␤-spectrin/ A ␥-globin transgene in erythroid tissues, 553A and 553C, the level of transgene expression was examined in nonerythroid tissues using RNase protection. The level of ␤-spectrin/ A ␥-globin mRNA (Fig. 10B ) was compared with the mRNA of the four murine ␣-globin genes (Fig.  10C ). ␤-Spectrin/ A ␥-globin gene expression/murine ␣-globin gene expression in individual tissues was compared with ␤-spectrin/ A ␥-globin gene expression/murine ␣-globin gene expression in bone marrow, with the percentage of expression in marrow equal to 100% (Fig. 11 ). There was essentially no expression in thymus, liver, kidney, and lung. Expression in heart and skeletal muscle ranged from 10 to 44%, with decreased expression in transgenic animals (with one exception) who were perfused with saline immediately prior to sacrificing. Expression levels in brain were variable, with minimal expression in line 553A and 10 -40% expression in line 553C.
DISCUSSION
Our studies show that a promoter of the human ␤-spectrin gene directs high levels of expression in erythroid cells at all stages of erythroid development. Although the genes encoding erythrocyte membrane proteins have been cloned for a number of years, there are very little data about the regulatory elements that control their expression. Until now, there have been no in vivo studies of elements involved in the regulation of these genes. In vitro studies of the promoters of glycophorin B and C, ankyrin-1, and band 3 (53-57), other red blood cell membrane proteins, have been performed. These studies demonstrate that, like the ␤-spectrin erythroid promoter, a combi- In adult blood, the human ␥-globin RNA/mouse ␣-globin RNA ratio corrected for transgene copy was 23% for line 553A and 40% for line 553C.
The Human ␤-Spectrin Gene Erythroid Promoternation of GATA-1 and CACCC-binding proteins appears to be essential for high level expression of these genes. Thus, the promoters of erythrocyte membrane protein genes share similarities to other erythroid gene promoters (49, 58 -60) .
The human ␤-spectrin erythroid promoter appears to be quite "compact" in that a relatively short fragment of DNA directs high level expression in erythroid cells. A number of erythroid gene promoters require distant regulatory elements (enhancers) to confer high levels of expression (49) . Additional regulatory elements not present in the DNA promoter fragment tested in vivo appear to be required for erythroid expression of the ␤-spectrin promoter, since only three of five mouse lines expressed the transgene.
Consensus binding sites for GATA-1 and CACCC-binding proteins are present in very close proximity in the ␤-spectrin promoter, mimicking other erythroid gene promoters (e.g. [61] [62] [63] [64] [65] [66] . This combination may lead to cooperation between GATA-1 and CACCC-binding proteins to enhance transcription (63, 66, 67) . Sp1 and EKLF have been both been shown to physically interact with GATA-1 in the regulatory elements of certain erythroid genes to synergistically activate transcription in transfected cells (68) .
CACCC-box binding proteins and members of the Kruppel family of transcription factors both bind CACCC and CGCCC sequences, although they show distinct binding preferences (Fig. 12) (39, 48 -50) . Although Sp1, BKLF, and to a much lesser degree EKLF were found to bind to the GC-rich, CACCCbinding region of the ␤-spectrin promoter in vitro, it is unknown what transcription factors bind this site in vivo. The interactions of Sp1 and/or BKLF with a broad spectrum of erythroid gene promoters make them likely candidates for binding to this site (39) . EKLF has been shown to bind to the CACCC-box consensus sequences of other non-globin, erythroid gene promoters, such as the ALAS-E gene (69) , and to increase expression directed by the glycophorin B promoter transiently transfected into GATA-1-expressing S2 cells, but these studies have been carried out in vitro. If EKLF does indeed bind the ␤-spectrin gene promoter, it will join the ␤-globin gene as a downstream target of EKLF. Additional studies, such as analysis of the ability of EKLF to act as a transcriptional activator of the ␤-spectrin gene promoter in Drosophila S2 cells that lack endogenous Sp1 and analysis of ␤-spectrin content in hematopoietic cells from EKLF Ϫ/Ϫ erythroid cells will shed additional light on this question. It is tempting to speculate what type of additional regulatory elements regulate the expression of ␤ spectrin in nonerythroid cells. In dystrophin, also a member of the spectrin superfamily of proteins, five autonomous promoters direct the transcription of alternate transcripts in a cell-specific and developmentally controlled manner (70) . Because alternate transcripts of ␤-spectrin are present in nonerythroid tissues, it is not unreasonable to postulate that these tissue-specific isoforms are controlled by alternate promoters. Studies of other erythrocyte membrane protein genes have shown that alternate promoters direct the expression of tissue-specific transcripts of ankyrin-1 and band 3 (41, 54, 56, (71) (72) (73) .
